Comparative Pharmacology
Head-to-head clinical analysis: AZLIN versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZLIN versus CLOXAPEN.
AZLIN vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azlin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
1-2 grams intravenously every 4-6 hours; total daily dose up to 12 grams for serious infections.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.0–1.5 hours in adults with normal renal function; prolonged to 3–5 hours in moderate renal impairment (CrCl 10–50 mL/min) and up to 10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Renal excretion of unchanged drug (approximately 60-70% via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <10%.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic